

Brigitte A B Essers

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6082178/publications.pdf>

Version: 2024-02-01

41
papers

2,132
citations

471509

17
h-index

302126

39
g-index

41
all docs

41
docs citations

41
times ranked

2545
citing authors

#	ARTICLE	IF	CITATIONS
1	The ICECAP-A instrument for capabilities: assessment of construct validity and test-retest reliability in a general Dutch population. <i>Quality of Life Research</i> , 2022, 31, 687-696.	3.1	7
2	The estimation of a preference-based single index for the IBS-QoL by mapping to the EQ-5D-5L in patients with irritable bowel syndrome. <i>Quality of Life Research</i> , 2022, 31, 1209-1221.	3.1	5
3	The ICEpop Capability Measure for Adults Instrument for Capabilities: Development of a Tariff for the Dutch General Population. <i>Value in Health</i> , 2022, 25, 125-132.	0.3	6
4	Endovascular treatment and neurosurgical clipping in subarachnoid hemorrhage: a systematic review of economic evaluations. <i>Journal of Neurosurgical Sciences</i> , 2022, , .	0.6	0
5	Discrete Choice Experiment Reveals Strong Preference for Dietary Treatment Among Patients With Irritable Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2628-2637.	4.4	11
6	Risk of Invasive Cutaneous Squamous Cell Carcinoma After Different Treatments for Actinic Keratosis. <i>JAMA Dermatology</i> , 2022, 158, 634.	4.1	18
7	Development of a patient decision aid for superficial basal cell carcinoma. <i>British Journal of Dermatology</i> , 2021, 184, 744-746.	1.5	1
8	What Tinnitus Therapy Outcome Measures Are Important for Patients? A Discrete Choice Experiment. <i>Frontiers in Neurology</i> , 2021, 12, 668880.	2.4	4
9	The Effect of Four Approaches to Treat Actinic Keratosis on the Health-Related QOL, as Assessed by the Skindex-29 and Actinic Keratosis QOL. <i>Journal of Investigative Dermatology</i> , 2021, 141, 1830-1832.	0.7	0
10	Ethics of ECPR research. <i>Resuscitation</i> , 2021, 169, 136-142.	3.0	10
11	A trial-based economic evaluation of peppermint oil for the treatment of irritable bowel syndrome. <i>United European Gastroenterology Journal</i> , 2021, 9, 997-1006.	3.8	7
12	Patient Preference for Optical Coherence Tomography versus Punch Biopsy as Diagnostic Strategy for Diagnosis of Basal Cell Carcinoma: A Labelled Discrete Choice Experiment. <i>Acta Dermato-Venereologica</i> , 2021, 102, adv00638.	1.3	1
13	Efficacy and Safety of Peppermint Oil in a Randomized, Double-Blind Trial of Patients With Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2020, 158, 123-136.	1.3	69
14	Age dependency of EQ-5D-Youth health states valuations on a visual analogue scale. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 386.	2.4	5
15	A discrete choice experiment to identify the most efficient quality indicators for the supervision of psychiatric hospitals. <i>BMC Health Services Research</i> , 2020, 20, 192.	2.2	1
16	Longitudinal Relationships between Asthma-Specific Quality of Life and Asthma Control in Children; The Influence of Chronic Rhinitis. <i>Journal of Clinical Medicine</i> , 2020, 9, 555.	2.4	2
17	A trial-based cost-effectiveness analysis of topical 5-fluorouracil vs. imiquimod vs. ingenol mebutate vs. methyl aminolaevulinate conventional photodynamic therapy for the treatment of actinic keratosis in the head and neck area performed in the Netherlands. <i>British Journal of Dermatology</i> , 2020, 183, 738-744.	1.5	27
18	Early or Delayed Cardioversion in Recent-Onset Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2019, 380, 1499-1508.	27.0	120

#	ARTICLE	IF	CITATIONS
19	Randomized Trial of Four Treatment Approaches for Actinic Keratosis. <i>New England Journal of Medicine</i> , 2019, 380, 935-946.	27.0	153
20	Quantitative survey into value clarification of discussed treatment options among patients treated for basal cell carcinoma. <i>British Journal of Dermatology</i> , 2019, 180, 1256-1257.	1.5	2
21	Early initiation of extracorporeal life support in refractory out-of-hospital cardiac arrest: Design and rationale of the INCEPTION trial. <i>American Heart Journal</i> , 2019, 210, 58-68.	2.7	38
22	Patient preferences for the attributes of a noninvasive treatment for superficial basal cell carcinoma: a discrete choice experiment. <i>British Journal of Dermatology</i> , 2018, 178, e26-e27.	1.5	5
23	Five-Year Results of a Randomized Controlled Trial Comparing Effectiveness of Photodynamic Therapy, Topical Imiquimod, and Topical 5-Fluorouracil in Patients with Superficial Basal Cell Carcinoma. <i>Journal of Investigative Dermatology</i> , 2018, 138, 527-533.	0.7	101
24	National mixed methods evaluation of the effects of removing legal barriers to full practice authority of Dutch nurse practitioners and physician assistants. <i>BMJ Open</i> , 2018, 8, e019962.	1.9	21
25	Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. <i>Lancet, The</i> , 2017, 389, 1312-1322.	13.7	364
26	Acute cardioversion vs a wait-and-see approach for recent-onset symptomatic atrial fibrillation in the emergency department: Rationale and design of the randomized ACWAS trial. <i>American Heart Journal</i> , 2017, 183, 49-53.	2.7	11
27	Intravenous hydration according to current guidelines in the prevention of contrast induced nephropathy—the AMACING trial. <i>Journal of Thoracic Disease</i> , 2017, 9, E656-E657.	1.4	6
28	Three-Year Follow-Up Results of Photodynamic Therapy vs. Imiquimod vs. Fluorouracil for Treatment of Superficial Basal Cell Carcinoma: A Single-Blind, Noninferiority, Randomized Controlled Trial. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1568-1574.	0.7	96
29	Survival or Mortality: Does Risk Attribute Framing Influence Decision-Making Behavior in a Discrete Choice Experiment?. <i>Value in Health</i> , 2016, 19, 202-209.	0.3	31
30	Functional outcome and cost-effectiveness of pulsed electromagnetic fields in the treatment of acute scaphoid fractures: a cost-utility analysis. <i>BMC Musculoskeletal Disorders</i> , 2015, 16, 84.	1.9	16
31	Cost-effectiveness of topical imiquimod and fluorouracil vs. photodynamic therapy for treatment of superficial basal-cell carcinoma. <i>British Journal of Dermatology</i> , 2014, 171, 1501-1507.	1.5	35
32	Electronic monitoring of symptoms and lung function to assess asthma control in children. <i>Annals of Allergy, Asthma and Immunology</i> , 2014, 113, 257-262.e1.	1.0	15
33	Eliciting patients' preferences for epilepsy diagnostics: A discrete choice experiment. <i>Epilepsy and Behavior</i> , 2014, 31, 102-109.	1.7	14
34	The development of quality indicators in mental healthcare: a discrete choice experiment. <i>BMC Psychiatry</i> , 2012, 12, 103.	2.6	6
35	Methods to measure treatment satisfaction in patients with pulmonary embolism or deep venous thrombosis. <i>Current Opinion in Pulmonary Medicine</i> , 2010, 16, 437-441.	2.6	5
36	Assessing the Public's Preference for Surgical Treatment of Primary Basal Cell Carcinoma: A Discrete-Choice Experiment in the South of The Netherlands. <i>Dermatologic Surgery</i> , 2010, 36, 1950-1955.	0.8	19

#	ARTICLE	IF	CITATIONS
37	Transferability of Model-Based Economic Evaluations: The Case of Trastuzumab for the Adjuvant Treatment of HER2-Positive Early Breast Cancer in the Netherlands. <i>Value in Health</i> , 2010, 13, 375-380.	0.3	29
38	Does the Inclusion of a Cost Attribute Result in Different Preferences for the Surgical Treatment of Primary Basal Cell Carcinoma?. <i>Pharmacoeconomics</i> , 2010, 28, 507-520.	3.3	32
39	Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up. <i>Lancet Oncology</i> , The, 2008, 9, 1149-1156.	10.7	390
40	Cost-effectiveness of Mohs Micrographic Surgery vs Surgical Excision for Basal Cell Carcinoma of the Face. <i>Archives of Dermatology</i> , 2006, 142, 187-94.	1.4	102
41	Surgical excision vs Mohs' micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial. <i>Lancet</i> , The, 2004, 364, 1766-1772.	13.7	347